This article was originally published in The Tan Sheet
"Submission of Abbreviated Reports and Synopses in Support of Marketing Applications" guidance, expected to appear in the Sept. 13 Federal Register, describes when studies that are part of an NDA may be submitted to FDA in abbreviated form and describes the format abbreviated submissions should follow. The agency estimates the resulting reduction in burden for industry will be 300 hours. A draft of the guidance appeared in the Sept. 21 Federal Register (1"The Tan Sheet" Sept. 28, 1998, p. 24). Comments may be submitted at any time
You may also be interested in...
Abbreviated data reports may be submitted for efficacy, safety and pharmacology studies that are not central to efficacy claims for a specific indication, FDA indicates in its guidance for industry on "Submission of Abbreviated Reports and Synopses in Support of Marketing Applications."
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning